For example, Papp KA et al. evaluate the efficacy and safety of different doses of secukinumab, anti-IL-17 A monoclonal antibody, in patients with moderate-to-severe plaque psoriasis [14]. This evidence concerns the gene IL17A and psoriasis vulgaris.